Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: Results of a phase I study

Journal of Immunotherapy

Volumn 22, Issue 5, 1999, Pages 407-414

  Filippo, Franco Di ^a   Rossi, Carlo R ^b   Vaglini, Maurizio ^c   Azzarelli, Alberto ^c   Anzà, Michele ^a   Santinami, Mario ^c   Lise, Mario ^b   Cavaliere, Francesco ^a   Giannarelli, Diana ^a   Quagliuolo, Vittorio ^a   Vecchiato, Antonella ^b   Deraco, Marcello ^c   Garinei, Rosa ^a   Foletto, Maria ^b   Botti, Claudio ^a   Cavaliere, Renato ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Doxorubicin; Perfusion; RTNF ; Soft tissue limb sarcoma

Indexed keywords

DOXORUBICIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; LIMB AMPUTATION; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

ADULT; AGED; AMPUTATION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032849248     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199909000-00004     Document Type: Article

References (24)

1. Cantin J, McNeer GP, Chu FC, et al. The problem of local recurrence after treatment of soft tissue sarcoma. Ann Surg 1968;168:47-53.
2. Russell WO, Cohen J, Enzinger F, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977;40:1562-70.
3. Rantakokko U. Sarcomas of the soft tissue in the extremities and limb girdles. Acta Chir Scand 1979;145:385-9.
4. Lindberg RD, Martin RG, Romsdahl MM, et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft tissue sarcomas. Cancer 1981;47:2391-8.
5. Simon MA, Enneking WF. The management of soft tissue sarcomas of the extremities. J Bone Joint Surg 1976;58:317-27.
6. Di Filippo F, Calabro AM, Cavallari A, et al. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg 1988;12:332-8.
7. Krementz ET. Regional perfusion. Current sophistication. What next? Cancer 1986;57:416-22.
8. Stehlin JS, Giovannella BC, Gutierrez AE, et al. 15 years’ experience with hyperthermic perfusion for treatment of soft tissue sarcoma and malignant melanoma of the extremities. Front Radiat Ther Oncol 1984;18:177-81.
9. Lehti PM, Stephen MH, Janoff K, et al. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986;162:149-54.
10. Di Filippo F, Cagol PP, Civalleri D, et al. Hyperthermic perfusion with doxorubicin: Phase I study. Reg Cancer Treat 1991; 4:13.
11. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic antiblastie perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140-6.
12. Lienard D, Ewalenko P, Delmatte J, et al. High dose recombinant TNF alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-8.
13. Di Filippo F, Giannarelli D, Botti C, et al. Hyperthermic antiblasic perfusion for the treatment of soft tissue sarcoma. Ann Oncol 1992;3:71-6.
14. Di Filippo F, Botti C, Giannarelli D, et al. Thermochemotherapy for soft tissue sarcomas. In: Pinedo HM, Verweij J, Suit HD, eds. Soft tissue sarcoma: new developments in the multidisciplinary approach to treatment. Boston, MA: Kluwer Academic Publishers, 1991, 127-47.
15. Wieberdink J, Benckhuijsen C, Braat RP, et al. Dosimetry in isolated perfusion of the limb by assessment of perfused volume and grading of toxic reaction. Eur J Cancer Clin Oncol 1982;18:905-10.
16. Baba H. Effect of whole body hyperthermia combined with adria-mycin on tumor and normal tissue in rats. 37th Annual Meeting of the Radiation Research Society and 9th Annual Meeting of the North American Hyperthermia Group, March 18-22, 1989, Seattle, WA, 1989: 34.
17. Alexander RB, Nelson WG, Coffey DS, et al. Synergistic enhancement of tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987;47:2403-6.
18. Niitsu Y, Wataname N, Umeno H et al. Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and metastasis. Cancer Res 1988;48:654-9.
19. Hill S, Fawcett WJ, Sheldon J, et al. Low dose TNF alpha and melphalan in hyperthermic isolated limb perfusion. Brit J Surg 1993;80:995-7.
20. Vaglini M, Santinami M, Manzi R, et al. Treatment of in transit metasases from cutaneous melanoma by isolation perfusion with tumor necrosis factor alpha (TNFα), melphalan and interferon gamma (IFN-γ). Dose finding experience at the National Cancer Institute of Milan. Melanoma Res 1994;4:35-8.
21. Eggimann P, Chiolero R, Chassot PG, et al. Systemic and hemodynamic effect of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 1995;107:1074-82.
22. Di Filippo F, Rossi RC, Anzå M, et al. Hyperthermic antiblastie perfusion with TNF and melphalan [Abstract T6], Proc VII Int Congr on Regional Cancer Treatment. September 11-13, Wiesbaden, Germany, 1995:89.
23. Eggermont AMM, Schraffordt Koops H, Kroon BBR, et al. European experience: 120 TNFα isolated limb perfusions for non resectable extremity soft tissue sarcoma [Abstract T10]. Proc of VII Int Congress on Regional Cancer Treatment, September 11-13, Wiesbaden, Germany, 1995:93.
24. Eggermont AMM, Schraffordt Koops H, Klauser JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-65.